Form 8-K - Current report:
SEC Accession No. 0001628280-24-036122
Filing Date
2024-08-08
Accepted
2024-08-08 16:06:55
Documents
16
Period of Report
2024-08-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K crdf-20240808.htm   iXBRL 8-K 31332
2 EX-99.1 crdf063024-q22024pr.htm EX-99.1 108226
6 crdf-20240808_g1.jpg GRAPHIC 2732
7 image_0.jpg GRAPHIC 7491
  Complete submission text file 0001628280-24-036122.txt   287341

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT crdf-20240808.xsd EX-101.SCH 1925
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT crdf-20240808_lab.xml EX-101.LAB 20770
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT crdf-20240808_pre.xml EX-101.PRE 12001
18 EXTRACTED XBRL INSTANCE DOCUMENT crdf-20240808_htm.xml XML 2607
Mailing Address 11055 FLINTKOTE AVENUE SAN DIEGO CA 92121
Business Address 11055 FLINTKOTE AVENUE SAN DIEGO CA 92121 858-952-7570
Cardiff Oncology, Inc. (Filer) CIK: 0001213037 (see all company filings)

EIN.: 272004382 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35558 | Film No.: 241188245
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)